Nurix Therapeutics
NRIX
125 hedge funds and large institutions have $1.17B invested in Nurix Therapeutics in 2021 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 43 increasing their positions, 36 reducing their positions, and 12 closing their positions.
18,450% more call options, than puts
Call options by funds: $371K | Put options by funds: $2K
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
19% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 36
11% more funds holding
Funds holding: 113 → 125 (+12)
1.76% more ownership
Funds ownership: 88.86% → 90.62% (+1.8%)
1% less capital invested
Capital invested by funds: $1.18B → $1.17B (-$14M)
44% less funds holding in top 10
Funds holding in top 10: 9 → 5 (-4)
Top Buyers
Top Sellers
NRIX Hedge Fund Activity: Q4 2021 in Review
125 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q4 2021, worth a combined $1.17B — down 1.2% from $1.18B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new NRIX positions and 12 closed out — a net gain of 12 holders — while 43 added to existing stakes and 36 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $20.3M. The largest seller was EcoR1 Capital, cutting an estimated $24.8M.
- 125 institutional investors held Nurix Therapeutics (NRIX) as of Q4 2021, up from 113 in Q3 2021.
- Funds reported $1.17B of Nurix Therapeutics stock for Q4 2021, down 1.2% quarter-over-quarter.
- 24 funds opened new Nurix Therapeutics positions in Q4 2021 and 12 closed out, a net change of +12 holders.
- The largest Nurix Therapeutics buyer in Q4 2021 was Eventide Asset Management, an estimated $20.3M added.
- The largest Nurix Therapeutics seller in Q4 2021 was EcoR1 Capital, an estimated $24.8M sold.
Based on aggregated 13F filings for Q4 2021.